ARTICLE | Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
February 21, 2024 12:11 AM UTC
The “gene placement” system from venture-backed Kelonia Therapeutics Inc. has attracted a new pharma partner, as Astellas Pharma Inc. (Tokyo:4503) is paying $40 million up front in a structured deal under which the partners will create in vivo CAR T therapies.
Launched nearly two years ago, Kelonia has developed a platform with which it can use lentiviral particles to deliver genetic cargoes to extrahepatic sites, with selectivity for specific tissues...